These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 18187275)
1. Susceptibility testing of tulathromycin: interpretative breakpoints and susceptibility of field isolates. Godinho KS Vet Microbiol; 2008 Jun; 129(3-4):426-32. PubMed ID: 18187275 [TBL] [Abstract][Full Text] [Related]
2. Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology. Godinho KS; Keane SG; Nanjiani IA; Benchaoui HA; Sunderland SJ; Jones MA; Weatherley AJ; Gootz TD; Rowan TG Vet Ther; 2005; 6(2):113-21. PubMed ID: 16094559 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath study. de Jong A; Thomas V; Simjee S; Moyaert H; El Garch F; Maher K; Morrissey I; Butty P; Klein U; Marion H; Rigaut D; Vallé M Vet Microbiol; 2014 Aug; 172(1-2):202-15. PubMed ID: 24837878 [TBL] [Abstract][Full Text] [Related]
4. Seven years survey of susceptibility to marbofloxacin of bovine pathogenic strains from eight European countries. Meunier D; Acar JF; Martel JL; Kroemer S; Vallé M Int J Antimicrob Agents; 2004 Sep; 24(3):268-78. PubMed ID: 15325431 [TBL] [Abstract][Full Text] [Related]
5. In vitro activities of tulathromycin and ceftiofur combined with other antimicrobial agents using bovine Pasteurella multocida and Mannheimia haemolytica isolates. Sweeney MT; Brumbaugh GW; Watts JL Vet Ther; 2008; 9(3):212-22. PubMed ID: 19003782 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of tulathromycin injectable solution for the treatment of naturally occurring Swine respiratory disease. Nutsch RG; Hart FJ; Rooney KA; Weigel DJ; Kilgore WR; Skogerboe TL Vet Ther; 2005; 6(2):214-24. PubMed ID: 16094568 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of tulathromycin in the treatment and prevention of natural outbreaks of bovine respiratory disease in European cattle. Godinho KS; Wolf RM; Sherington J; Rowan TG; Sunderland SJ; Evans NA Vet Ther; 2005; 6(2):122-35. PubMed ID: 16094560 [TBL] [Abstract][Full Text] [Related]
8. Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers. Sarchet JJ; Pollreisz JP; Bechtol DT; Blanding MR; Saltman RL; Taube PC PLoS One; 2022; 17(2):e0247213. PubMed ID: 35143504 [TBL] [Abstract][Full Text] [Related]
9. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis. Blondeau JM; Fitch SD PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633 [TBL] [Abstract][Full Text] [Related]
10. Monitoring of antimicrobial susceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across Europe, 2009-2012: VetPath results. El Garch F; de Jong A; Simjee S; Moyaert H; Klein U; Ludwig C; Marion H; Haag-Diergarten S; Richard-Mazet A; Thomas V; Siegwart E Vet Microbiol; 2016 Oct; 194():11-22. PubMed ID: 27102206 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antimicrobial activity of florfenicol against bacteria isolated from bovine and porcine respiratory disease. Shin SJ; Kang SG; Nabin R; Kang ML; Yoo HS Vet Microbiol; 2005 Mar; 106(1-2):73-7. PubMed ID: 15737475 [TBL] [Abstract][Full Text] [Related]
12. Survey of marbofloxacin susceptibility of bacteria isolated from cattle with respiratory disease and mastitis in Europe. Kroemer S; Galland D; Guérin-Faublée V; Giboin H; Woehrlé-Fontaine F Vet Rec; 2012 Jan; 170(2):53. PubMed ID: 22121154 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility patterns and sensitivity to tulathromycin in goat respiratory bacterial isolates. Clothier KA; Kinyon JM; Griffith RW Vet Microbiol; 2012 Apr; 156(1-2):178-82. PubMed ID: 22078276 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves. Godinho KS; Rae A; Windsor GD; Tilt N; Rowan TG; Sunderland SJ Vet Ther; 2005; 6(2):96-112. PubMed ID: 16094558 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility patterns of respiratory tract pathogens from sheep and goats. Berge AC; Sischo WM; Craigmill AL J Am Vet Med Assoc; 2006 Oct; 229(8):1279-81. PubMed ID: 17042733 [TBL] [Abstract][Full Text] [Related]
16. Results of the antimicrobial agent susceptibility study raised in a representative, cross-sectional monitoring study on a national basis. Kaspar H Int J Med Microbiol; 2006 Jun; 296 Suppl 41():69-79. PubMed ID: 16531116 [TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of ceftiofur against Australian isolates of the family Pasteurellaceae associated with respiratory disease in cattle and pigs. Blackall PJ; Pahoff JL; Stephens CP; Darvill FM Aust Vet J; 1996 Jul; 74(1):71. PubMed ID: 8894010 [No Abstract] [Full Text] [Related]
18. Monitoring of antimicrobial resistance in pathogenic bacteria from livestock animals. Wallmann J Int J Med Microbiol; 2006 Jun; 296 Suppl 41():81-6. PubMed ID: 16530479 [TBL] [Abstract][Full Text] [Related]
19. Changes in antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from pigs in Spain during the last decade. Gutiérrez-Martín CB; del Blanco NG; Blanco M; Navas J; Rodríguez-Ferri EF Vet Microbiol; 2006 Jun; 115(1-3):218-22. PubMed ID: 16431040 [TBL] [Abstract][Full Text] [Related]
20. A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida. Lees P; Illambas J; Potter TJ; Pelligand L; Rycroft A; Toutain PL J Vet Pharmacol Ther; 2017 Oct; 40(5):419-428. PubMed ID: 27891615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]